Aktuellt
SENASTE
Fluoguide reported Q1 results and provided an update on its clinical programme that will see head and neck cancer increasingly prioritised over lung cancer in the development timeline. We expect positive readouts from several major trials over the remainder of 2023 that investors should keep a close eye on, as they are major de-risking events in our view.
LÄS MER
